GC Biopharma exports Alyglo to US

The S.Korean pharmaceutical company shipped the initial volume of its immunoglobulin blood product to the US

GC Biopharma exports Alyglo to US
Young-Ae Lee 1
2024-07-09 11:29:30 0ae@hankyung.com
Bio & Pharma

South Korea’s major pharmaceutical company GC Biopharma Corp. announced on Monday that it shipped the initial volume of Alygro, its immunoglobulin blood product to enter the US market.  

Alyglo, which received approval from the US Food and Drug Administration (FDA) in December last year, is the primary humoral immunodeficiency (PHI) treatment. 

(Courtesy of GC Biopharma)
(Courtesy of GC Biopharma)

The US is the world’s largest immunoglobin market with a value of around 16 trillion won ($11.6 billion).

The initial shipment will reach patients through specialty pharmacies across the US by mid-July.

GC Biopharma has been actively preparing for its US launch.

It secured a key partnership on July 1 with a major US Pharmacy Benefit Manager (PBM) to list Alyglo covered on their formularies (lists of approved drugs).

The company signed contracts with reputable specialty pharmacies and distributors to build a strong distribution network.

The company aims to $50 million in Alyglo sales this year and projects annual growth to capture a market share in the US. 

Write to Young-Ae Lee at 0ae@hankyung.com
#GC Biopharma #Alygro #immunoglobulin blood product #US #export #PHI treatment #PBM

GC Biopharma aims to boost Alyglo sales sixfold in the US

GC Biopharma aims to boost Alyglo sales sixfold in the US

GC Biopharma’s Alyglo production line at its Ochang plant in South Korea (Courtesy of GC Biopharma) CHEONGJU, North Chungcheong Province -- South Korea’s major pharmaceutical company GC Biopharma Corp. aims to raise the sales of Alyglo, its immunoglobulin blood product approved by t

GC Biopharma gets FDA approval for Alyglo

GC Biopharma gets FDA approval for Alyglo

South Korea’s GC Biopharma Corp. announced on Monday that it received approval from the US Food and Drug Administration (FDA) for the immunoglobulin blood product Alyglo (intravenous immunoglobulin 10%.)Alyglo is the treatment for primary humoral immunodeficiency. GC Biopharma submitte

GC Biopharma breaks ground on blood product plant in Indonesia

GC Biopharma breaks ground on blood product plant in Indonesia

South Korea’s GC Biopharma Corp. broke ground on Wednesday on Indonesia’s first blood product plant through technology transfer.Indonesian pharmaceutical companies PT Triman and PT Medquest Jaya Global held a groundbreaking ceremony for the blood product factory in Jababeka Industr
(* comment hide *}